Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02200848
Title Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory CLL
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Georgetown University
Indications

chronic lymphocytic leukemia

Therapies

Ibrutinib + Lenalidomide + Rituximab

Age Groups: adult
Covered Countries USA


No variant requirements are available.